Therefore, the use of AAT ASO treatment in models of AAT Z-polymer associated liver disease warrants further exploration to determine if there is a benefit of this therapy in combination with AAT augmentation therapy for individuals at risk for COPD development. Here, SERPINA1 is linked to liver disorder.